A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Tantai, Narisa ^a,b,c   Chaikledkaew, Usa ^b,c   Tanwandee, Tawesak ^a   Werayingyong, Pitsaphun ^c   Teerawattananon, Yot ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

Chronic disease; Cost utility analysis; Hepatitis B; Treatment

Indexed keywords

ADENINE; ANTIVIRUS AGENT; ESSENTIAL DRUG; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH SERVICES RESEARCH; HEPATITIS B, CHRONIC; HUMAN; IMMUNOLOGY; MALE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; THAILAND; TREATMENT OUTCOME;

ADENINE; ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUGS, ESSENTIAL; FEMALE; HEALTH SERVICES RESEARCH; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MARKOV CHAINS; MODELS, ECONOMIC; ORGANOPHOSPHONATES; QUALITY-ADJUSTED LIFE YEARS; THAILAND; TREATMENT OUTCOME;

EID: 84899586054     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-170     Document Type: Article

References (59)

1. Hepatitis B. [ http://www.who.int/immunization/topics/hepatitis-b/en/ ]
2. The economics of treating chronic hepatitis B in Asia. Dan YY, Aung MO, Lim SG, Hepatol Int 2008 2 3 284 295 10.1007/s12072-008-9049-2 19669256
3. Chronic hepatitis B-new goals, new treatment. Lai CL, Yuen MF, N Engl J Med 2008 359 23 2488 2491 10.1056/NEJMe0808185 19052131
4. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T, Hepatology 2010 51 1 73 80 10.1002/hep.23246 19998272
5. Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B. Chen W, Hou JL, Zhonghua Gan Zang Bing Za Zhi 2009 17 8 569 573 19719912
6. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Buti M, Casado MA, Calleja JL, Salmeron J, Aguilar J, Rueda M, Esteban R, Aliment Pharmacol Ther 2006 23 3 409 419 10.1111/j.1365-2036.2006.02767.x 16423000 (Pubitemid 43382021)
7. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A, Health Technol Assess 2009 13 35 1 172 iii
8. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil. Costa AM, Li G, Nita ME, Araujo ES, Braz J Infect Dis 2008 12 5 368 373 19219274
9. Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B. Calcagno JI, Augustovski F, Gadano A, Souto A, Yuan Y, Acta Gastroenterol Latinoam 2008 38 4 260 273 19157381
10. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG, Aliment Pharmacol Ther 2008 27 12 1240 1252 10.1111/j.1365-2036.2008.03691.x 18373637 (Pubitemid 351697278)
11. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG, Pharmacoeconomics 2007 25 11 963 977 10.2165/00019053-200725110-00006 17960954 (Pubitemid 350014529)
12. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. Yuan Y, Iloeje UH, Hay J, Saab S, J Manag Care Pharm 2008 14 1 21 33 (Pubitemid 351325191)
13. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. Buti M, Brosa M, Casado MA, Rueda M, Esteban R, J Hepatol 2009 51 4 640 646 10.1016/j.jhep.2009.04.013 19576651
14. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Spackman DE, Veenstra DL, Pharmacoeconomics 2008 26 11 937 949 10.2165/00019053-200826110-00006 18850763
15. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Arnold E, Yuan Y, Iloeje U, Cook G, Appl Health Econ Health Policy 2008 6 4 231 246 10.1007/BF03256136 19382822
16. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Yuan Y, Iloeje U, Li H, Hay J, Yao GB, Value Health 2008 11 Suppl 1 11 S22 18387054
17. Pharmacoeconomics of entecavir treatment for chronic hepatitis B. You JH, Chan FW, Expert Opin Pharmacother 2008 9 15 2673 2681 10.1517/14656566.9.15. 2673 18803453
18. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Aggarwal R, Ghoshal UC, Naik SR, Natl Med J India 2002 15 6 320 327 12540064 (Pubitemid 36113659)
19. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Brooks EA, Lacey LF, Payne SL, Miller DW, Am J Manag Care 2001 7 7 677 682 11464426 (Pubitemid 32663924)
20. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM, Ann Intern Med 2005 142 10 821 831 10.7326/0003-4819-142-10- 200505170-00007 15897532 (Pubitemid 40664041)
21. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK, Value Health 2008 11 2 131 138 10.1111/j.1524-4733.2007. 00221.x 18380625 (Pubitemid 351473598)
22. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. Crowley S, Tognarini D, Desmond P, Lees M, Saal G, J Gastroenterol Hepatol 2002 17 2 153 164 10.1046/j.1440-1746.2002.02673.x 11966945 (Pubitemid 34415668)
23. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK, Eur J Gastroenterol Hepatol 2007 19 8 631 638 10.1097/MEG.0b013e3281108079 17625431 (Pubitemid 47067060)
24. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. Sun X, Qin WX, Li YP, Jiang XH, J Gastroenterol Hepatol 2007 22 9 1369 1377 10.1111/j.1440-1746. 2007.05068.x 17716343 (Pubitemid 47274592)
25. Liver Soceity Thailand, Thailand Consensus Recommendations for Management of Chronic Hepatitis B and C 2009 2010
26. 2008 APASL guidelines for HBV management. Liaw YF, Liver Reasearch Unit, Chang Gung Memorial Hospital and Chang Gung University, Taipei, Taiwan 2008
27. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group, N Engl J Med 2005 352 26 2682 2695 10.1056/NEJMoa043470 15987917 (Pubitemid 41007823)
28. EASL Clinical Practice Guidelines: management of chronic hepatitis B. European Association For The Study Of The Liver, J Hepatol 2009 50 2 227 242 19054588
29. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A, J Health Serv Res Policy 2005 10 4 245 250 10.1258/135581905774414187 16259692 (Pubitemid 41540277)
30. Clinical Efficacy of Chronic Hepatitis B Treatment for Patients with HBeAg-Positive Indirect Comparison: Network Meta-Analysis. Tantai N, Lerdkiattikorn P, Chaikledkaew U, Tanwandee T, Werayingyong P, Teerawattananon T, Mahidol J Pharm Sci 2012 39 2 46 49
31. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. McMahon BJ, Holck P, Bulkow L, Snowball M, Ann Intern Med 2001 135 9 759 768 10.7326/0003-4819-135-9-200111060-00006 11694101 (Pubitemid 33051260)
32. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Adefovir Dipivoxil 437 Study Group, N Engl J Med 2003 348 9 808 816 10.1056/NEJMoa020681 12606735 (Pubitemid 36245757)
33. A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis. Jang JW, Lee YC, Kim MS, Lee SY, Bae SH, Choi JY, Yoon SK, J Viral Hepat 2007 14 3 169 175 10.1111/j.1365-2893.2006.00788.x 17305882
34. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. Xu B, Hu DC, Rosenberg DM, Jiang QW, Lin XM, Lu JL, Robinson NJ, J Gastroenterol Hepatol 2003 18 12 1345 1352 10.1046/j.1440-1746.2003.03187.x 14675261 (Pubitemid 38045846)
35. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G, Gastroenterology 1997 112 2 463 472 10.1053/gast.1997.v112.pm9024300 9024300 (Pubitemid 27078833)
36. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, Santos J, Coll S, Morillas RM, Sola R, J Hepatol 2004 40 5 823 830 10.1016/j.jhep.2004.01.005 15094231 (Pubitemid 38507364)
37. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, Andrade RJ, Gonzalez-Serrano M, Aguilar J, Aguilar-Guisado M, Navarro JM, Salmerón J, Caballero-Granado FJ, García-García JA, Grupo Andaluz para el Estudio de las Enfermedades Infecciosas, Hepatology 2005 41 4 779 789 10.1002/hep.20626 15800956 (Pubitemid 40462940)
38. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL, Antivir Ther 2007 12 8 1295 1303 18240869
39. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T, Shoji B, Takaki A, Iwasaki Y, Sakaguchi K, Shiratori Y, Yamamoto K, J Gastroenterol Hepatol 2008 23 5 794 803 10.1111/j.1440-1746.2007.05240.x 18086120 (Pubitemid 351519425)
40. Lamivudine for patients with chronic hepatitis B and advanced liver disease. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group, N Engl J Med 2004 351 15 1521 1531 10.1056/NEJMoa033364 15470215 (Pubitemid 39315319)
41. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ, J Hepatol 2010 52 2 176 182 10.1016/j.jhep.2009.11.007 20006394
42. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM, J Viral Hepat 2005 12 4 386 392 10.1111/j.1365-2893.2005.00608.x 15985009 (Pubitemid 40961478)
43. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E, Hepatology 2003 37 4 748 755 10.1053/jhep.2003.50117 12668966 (Pubitemid 36397384)
44. Lamivudine Treatment in Patients with HBV-related Hepatocellular Carcinoma-using an Untreated, Matched Control Cohort. Piao C-Y, Acta Med Okayama 2005 59 5 217 224 16286955 (Pubitemid 43143776)
45. The Thai Working Group on Burden of Disease and Injuries, Burden of Disease and Injuries in Thailand: Priority Setting for Policy 2002
46. Ministry of Public Health, Reference Price Database of the Drugs and Medical Supplies Information Center (DMSIC) 2010
47. Reimbursement List of Medical Services. The Comptroller General's Department, Ministry of Finance 2009
48. Resource utilization and direct medical cost of chronic hepatitis C (CHC) in Thailand: a heavy but manageable economic burden. Thongsawat S, ISPOR 12th Annual European Congress: 24-27 October 2009 2009; Paris, France 2009
49. Minimum wage rate. [ http://www.labour.go.th/en/ ]
50. Comsumer Price Index in February 2010. [ http://www.indexpr.moc.go.th/ price-present/cpi/data/index-47.asp?list-month=02&list-year= 2553&list-region=country ]
51. Handling time in economic evaluation studies. Permsuwan U, Guntawongwan K, Buddhawongsa P, J Med Assoc Thai 2008 91 suppl 2 53 S58
52. Rates of Exchange of Commercial Banks in Bangkok Metropolis. [ http://www2.bot.or.th/statistics/ReportPage.aspx?reportID=123&language=eng ]
53. PPP conversion factor, private consumption. [ http://data.worldbank.org/ indicator/PA.NUS.PRVT.PP ]
54. The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH, Value Health 2008 11 3 527 538 10.1111/j.1524-4733.2007.00297.x 18179664 (Pubitemid 351712982)
55. Appropriate Threshold in Thailand. National List of Essential Drugs, National List of Essential Drug Meeting on December 20, 2007 Chaiyanadnarainthorn Meeting Room, Thai Food and Drug Administration; 2550.
56. 2012 National List of Essential Drugs. [ http://www.nlem.in.th/sites/ default/files/ratchakitcha-1-55.pdf ]
57. Viread Prescribing Guidelines. U.S. Food and Drug Administration 2006
58. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M, Gastroenterology 2003 125 6 1714 1722 10.1053/j.gastro.2003.09.033 14724824 (Pubitemid 37500436)
59. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Duarte-Rojo A, Heathcote EJ, Therap Adv Gastroenterol 2010 3 2 107 119 21180595